A real-life study including 4,784 men has been carried out by Stavanger University Hospital showing that the company’s blood-based Stockholm3 test leads to a 28% reduction in prostate cancer work-up, an increase in identification of clinically significant cancers by 55% and reduction of direct healthcare costs by 23-28%.
A3P announced today that a real-life study has been carried out by Stavanger University Hospital. The study included 4,784 men where GPs were instructed to use Stockholm3 instead of PSA as standard procedure for diagnosis of prostate cancer. Using Stockholm3 led to a 28% reduction in prostate cancer work-up, an increase in identification of clinically significant cancers by 55% and reduction of direct healthcare costs by 23-28%.
“This is the second major real-life study that shows both the strong clinical value of Stockholm3 as well as the major health economic gains. By replacing PSA with Stockholm3, healthcare providers significantly improve the outcome for men and at the same time make significant cost savings, a win-win for everyone” says Martin Steinberg, CEO of A3P Biomedical
“I believe Stockholm3 will change clinical practice in Scandinavia and thereafter in most Western countries, since the gains are so big compared to PSA”, says Svein R Kjosavik, Principal Investigator at Stavanger University Hospital to the Norwegian Doctors’ Society.
The study publication can be found here. The Norwegian Doctors’ Society’s interview with Svein R Kjosavik can be found here.